Postpartial gland cryoablation outcomes
Catheter duration (days), median (IQR) | 6 (3–7) |
PSA decrease from baseline (ng/ml), median (IQR) | 4.3 (2–6.2) |
MRI findings | |
% decrease in prostate volume from baseline, median (IQR) | 18.3 (0–28.0) |
Max PI-RADS V.2, n (%) | |
No lesions/not identified | 15 (48.40) |
2 | 2 (6.45) |
3 | 5 (16.13) |
4 | 7 (22.57) |
5 | 2 (6.45) |
Post-treatment targeted biopsy (max GG), n (%) | |
Benign | 15 (42.86) |
1 | 7 (20.0) |
2 | 11 (31.43) |
3 | 1 (2.86) |
4 | 1 (2.86) |
Recurrence, n (%) | |
In-field | 7 (20.00) |
Out-of-field | 6 (17.14) |
Ablated site | 10 (28.57) |
Non-ablated site | 3 (8.57) |
Post-treatment plan, n (%) | |
Active surveillance | 24 (68.57) |
Repeat PGC | 5 (14.29) |
Radical prostatectomy | 3 (8.57) |
Radiation treatment | 3 (8.57) |
GG, grade group; PGC, prostate gland cryoablation; PI-RADS V.2, Prostate Imaging-Reporting and Data System V.2; PSA, prostate specific antigen.